Tresiba and Ryzodeq Approved by EU Regulators

European regulators have approved Novo Nordisk’s Tresiba and Ryzodeg, which Novo hopes will challenge Sanofi’s Lantus, the largest selling insulin product globally. The European Commission have granted marketing authorisations for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults.

Continue Reading

Novo Nordisk Increase Staff in Emerging Markets

Novo Nordisk has revealed plans to expand their treatment for diabetes in emerging markets by employing roughly 1,000 additional employees over the next two years. Some of the emerging markets that Novo Nordisk are planning to expand in include Egypt, Vietnam, Colombia, Malaysia, Ukraine and Indonesia. As the pharmaceutical market in Europe, for example, slows

Continue Reading

Enlight Forms Two New Partnerships

Enlight Biosciences LLC announced yesterday that they have formed new partnerships with AstraZeneca and Novo Nordisk.  As partners, AstraZeneca and Novo Nordisk will have the chance to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs. Enlight is a unique entrepreneurial partnership with major pharmaceutical companies and leading

Continue Reading

Novo Nordisk Files Insulin Drugs to Rival Sanofi’s Lantus in Europe

Novo Nordisk has filed two marketing authorisation applications for approval to the European Medical Agency for their ultra long-acting insulin Degludec and insulin combination analogue DegludecPlus. The submissions are based on results from the BEGIN and BOOST clinical trial programmes which involved nearly 10,000 type 1 and type 2 diabetes patients. Data from the trials

Continue Reading